DK3565844T3 - Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer - Google Patents
Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer Download PDFInfo
- Publication number
- DK3565844T3 DK3565844T3 DK18704101.7T DK18704101T DK3565844T3 DK 3565844 T3 DK3565844 T3 DK 3565844T3 DK 18704101 T DK18704101 T DK 18704101T DK 3565844 T3 DK3565844 T3 DK 3565844T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444336P | 2017-01-09 | 2017-01-09 | |
| US201762477423P | 2017-03-27 | 2017-03-27 | |
| US201762491220P | 2017-04-27 | 2017-04-27 | |
| US201762556386P | 2017-09-09 | 2017-09-09 | |
| PCT/US2018/013029 WO2018129559A1 (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3565844T3 true DK3565844T3 (da) | 2023-05-01 |
Family
ID=61188903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18704101.7T DK3565844T3 (da) | 2017-01-09 | 2018-01-09 | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11407830B2 (da) |
| EP (2) | EP3565844B8 (da) |
| JP (2) | JP7110206B6 (da) |
| KR (1) | KR102606252B1 (da) |
| CN (1) | CN110382545A (da) |
| AU (1) | AU2018206481A1 (da) |
| BR (1) | BR112019014187A2 (da) |
| CA (1) | CA3049440A1 (da) |
| DK (1) | DK3565844T3 (da) |
| ES (1) | ES2945745T3 (da) |
| FI (1) | FI3565844T3 (da) |
| HU (1) | HUE061842T2 (da) |
| IL (1) | IL267804A (da) |
| MA (1) | MA47208A (da) |
| MX (1) | MX2019008207A (da) |
| PL (1) | PL3565844T3 (da) |
| PT (1) | PT3565844T (da) |
| SG (2) | SG11201906192SA (da) |
| TW (1) | TWI767976B (da) |
| WO (1) | WO2018129559A1 (da) |
| ZA (1) | ZA201904316B (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
| TWI773694B (zh) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| SG11201903835WA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against programmed death- 1 (pd-1) |
| WO2018129559A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ， インコーポレイテッド | 癌を処置する併用療法 |
| TW201927304A (zh) | 2017-09-26 | 2019-07-16 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
| EP3860988A1 (en) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| TW202028181A (zh) | 2018-10-03 | 2020-08-01 | 美商提薩羅有限公司 | 尼拉帕尼（niraparib）鹽 |
| US20200199567A1 (en) * | 2018-12-20 | 2020-06-25 | Medimmune, Llc | Methods for selection and expansion of t cells expressing pd-1 |
| AU2020282791A1 (en) * | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| IL293753A (en) | 2019-12-18 | 2022-08-01 | Tesaro Inc | Biopharmaceutical preparations and related methods |
| CA3163564A1 (en) * | 2019-12-31 | 2021-07-08 | Xiaokun SHEN | A drug combination for treating tumors and its application |
| US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| EP4060346A4 (en) * | 2020-02-18 | 2023-12-13 | Innobation Bio Co., Ltd. | COMPANION DIAGNOSTIC BIOMARKER COMPOSITION AND COMPANION DIAGNOSTIC KIT CONTAINING SAME |
| IL298946A (en) * | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists |
| WO2022025482A1 (ko) * | 2020-07-29 | 2022-02-03 | 재단법인 아산사회복지재단 | 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| WO2023153763A1 (ko) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| JPH09500783A (ja) | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
| AU7309601A (en) | 2000-06-28 | 2002-01-08 | Genetics Inst | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US7414171B2 (en) | 2000-11-15 | 2008-08-19 | Ono Pharmaceutical Co., Ltd. | PD-1-lacking mouse and use thereof |
| MXPA03008959A (es) | 2001-04-02 | 2004-10-15 | Wyeth Corp | Pd-1, un receptor para b7-4 y sus usos. |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| EP1445264B1 (en) | 2001-07-31 | 2011-09-14 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| DK2206517T3 (da) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| ES2608316T3 (es) | 2005-06-08 | 2017-04-07 | Dana-Farber Cancer Institute, Inc. | Métodos y composiciones para el tratamiento del cáncer e infecciones persistentes mediante la inhibición de la ruta de la muerte celular 1 (PD-1) programada |
| WO2006138739A2 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| EP2889309B1 (en) | 2006-03-03 | 2017-12-27 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of pd-1 or pd-l1 |
| PL2074145T3 (pl) * | 2006-10-02 | 2017-11-30 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| SI2079760T1 (sl) | 2006-12-27 | 2016-11-30 | Emory University | Sestavki in metode za zdravljenje okužb |
| PL2336120T3 (pl) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP) |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| PT2131860E (pt) | 2007-03-20 | 2014-03-04 | Lilly Co Eli | Anticorpos antiesclerostina |
| JP5577243B2 (ja) | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2307050A4 (en) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2350129B1 (en) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Ｐｄ−１特異抗体およびその使用 |
| CA2736816C (en) | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| JP5520961B2 (ja) | 2008-11-28 | 2014-06-11 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための方法 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| AU2010315304B2 (en) * | 2009-11-04 | 2014-03-27 | Merck Sharp & Dohme Llc | Engineered anti-TSLP antibody |
| WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011115996A1 (en) | 2010-03-17 | 2011-09-22 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
| AU2011227335B2 (en) * | 2010-03-17 | 2014-11-06 | Abbott Research B.V. | Anti-nerve growth factor (NGF) antibody compositions |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| WO2012017003A1 (en) | 2010-08-05 | 2012-02-09 | F. Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
| US20130217656A1 (en) | 2010-08-12 | 2013-08-22 | Beth Israel Deaconess Medical Center Inc | Methods and compositions for diagnosing and treating lupus |
| WO2012031122A2 (en) | 2010-09-03 | 2012-03-08 | Immport Therapeutics, Inc. | Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| TWI496886B (zh) | 2011-06-24 | 2015-08-21 | Taipei Veteran General Hospital | 提升感染性與惡性疾病之治療之免疫反應 |
| EP2742953B1 (en) | 2011-08-11 | 2021-09-22 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2013177102A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
| WO2013174997A1 (en) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies |
| EP2855528B1 (en) | 2012-05-31 | 2019-06-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| MX2015015037A (es) | 2013-05-02 | 2016-07-08 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). |
| US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CN106255510A (zh) * | 2014-03-05 | 2016-12-21 | 百时美施贵宝公司 | 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌 |
| BR112016018408A2 (pt) | 2014-03-14 | 2017-12-26 | Immutep Sas | moléculas de anticorpo à lag-3 e usos das mesmas |
| JP6682498B2 (ja) | 2014-03-24 | 2020-04-15 | キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
| ES2783424T3 (es) | 2014-06-19 | 2020-09-17 | Regeneron Pharma | Animales no humanos que tienen un gen de muerte celular programada 1 humanizado |
| AU2015298356B2 (en) | 2014-08-05 | 2020-11-19 | MabQuest SA | Immunological reagents binding to pd-1 |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MX2017005258A (es) | 2014-10-31 | 2017-07-26 | Oncomed Pharm Inc | Terapia combinada para tratamiento de enfermedad. |
| MA41218A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| DK3240801T3 (da) | 2014-12-31 | 2021-02-08 | Checkmate Pharmaceuticals Inc | Kombinationstumorimmunterapi |
| US20170152323A1 (en) | 2015-01-16 | 2017-06-01 | Immunwork Inc. | Anti-inflammatory molecules with tissue-targeting functions |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| RS60753B1 (sr) * | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
| NZ749413A (en) | 2016-06-29 | 2023-05-26 | Tesaro Inc | Methods of treating ovarian cancer |
| SG11201903835WA (en) * | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against programmed death- 1 (pd-1) |
| EA201990741A1 (ru) * | 2016-11-29 | 2019-11-29 | Антитела, направленные против белка-1 запрограммированной смерти (pd-1) | |
| WO2018129559A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| MA47206A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
-
2018
- 2018-01-09 WO PCT/US2018/013029 patent/WO2018129559A1/en unknown
- 2018-01-09 MA MA047208A patent/MA47208A/fr unknown
- 2018-01-09 SG SG11201906192SA patent/SG11201906192SA/en unknown
- 2018-01-09 SG SG10201913075RA patent/SG10201913075RA/en unknown
- 2018-01-09 CN CN201880016132.XA patent/CN110382545A/zh active Pending
- 2018-01-09 PT PT187041017T patent/PT3565844T/pt unknown
- 2018-01-09 BR BR112019014187-1A patent/BR112019014187A2/pt unknown
- 2018-01-09 ES ES18704101T patent/ES2945745T3/es active Active
- 2018-01-09 EP EP18704101.7A patent/EP3565844B8/en active Active
- 2018-01-09 KR KR1020197023407A patent/KR102606252B1/ko active IP Right Grant
- 2018-01-09 CA CA3049440A patent/CA3049440A1/en active Pending
- 2018-01-09 DK DK18704101.7T patent/DK3565844T3/da active
- 2018-01-09 PL PL18704101.7T patent/PL3565844T3/pl unknown
- 2018-01-09 JP JP2019537103A patent/JP7110206B6/ja active Active
- 2018-01-09 AU AU2018206481A patent/AU2018206481A1/en active Pending
- 2018-01-09 EP EP23158731.2A patent/EP4219563A3/en active Pending
- 2018-01-09 FI FIEP18704101.7T patent/FI3565844T3/fi active
- 2018-01-09 HU HUE18704101A patent/HUE061842T2/hu unknown
- 2018-01-09 TW TW107100822A patent/TWI767976B/zh active
- 2018-01-09 MX MX2019008207A patent/MX2019008207A/es unknown
- 2018-01-09 US US16/476,536 patent/US11407830B2/en active Active
-
2019
- 2019-06-28 ZA ZA2019/04316A patent/ZA201904316B/en unknown
- 2019-07-02 IL IL267804A patent/IL267804A/en unknown
-
2022
- 2022-04-11 JP JP2022065095A patent/JP2022082809A/ja active Pending
- 2022-07-15 US US17/812,933 patent/US20230111418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL267804A (en) | 2019-09-26 |
| WO2018129559A1 (en) | 2018-07-12 |
| SG11201906192SA (en) | 2019-08-27 |
| KR20190114996A (ko) | 2019-10-10 |
| CN110382545A (zh) | 2019-10-25 |
| EP4219563A3 (en) | 2023-10-04 |
| JP7110206B6 (ja) | 2022-08-25 |
| SG10201913075RA (en) | 2020-02-27 |
| MA47208A (fr) | 2019-11-13 |
| ZA201904316B (en) | 2022-12-21 |
| JP2022082809A (ja) | 2022-06-02 |
| US11407830B2 (en) | 2022-08-09 |
| EP3565844B1 (en) | 2023-03-01 |
| TWI767976B (zh) | 2022-06-21 |
| KR102606252B1 (ko) | 2023-11-23 |
| PT3565844T (pt) | 2023-05-02 |
| US20230111418A1 (en) | 2023-04-13 |
| US20200239574A1 (en) | 2020-07-30 |
| EP3565844B8 (en) | 2023-04-12 |
| HUE061842T2 (hu) | 2023-08-28 |
| MX2019008207A (es) | 2019-12-11 |
| JP2020504141A (ja) | 2020-02-06 |
| AU2018206481A1 (en) | 2019-07-25 |
| TW201831200A (zh) | 2018-09-01 |
| CA3049440A1 (en) | 2018-07-12 |
| JP7110206B2 (ja) | 2022-08-01 |
| ES2945745T3 (es) | 2023-07-06 |
| FI3565844T3 (fi) | 2023-05-09 |
| EP3565844A1 (en) | 2019-11-13 |
| PL3565844T3 (pl) | 2023-06-12 |
| EP4219563A2 (en) | 2023-08-02 |
| BR112019014187A2 (pt) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3565844T3 (da) | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer | |
| ES2966890T3 (es) | Nuevos anticuerpos anti-PD-L1 | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| HK1252272A1 (zh) | 使用抗ox40抗體治療癌症的方法 | |
| DK3394103T3 (da) | Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling | |
| HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| DK3551660T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| DK3142751T3 (da) | Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer | |
| CL2016002462A1 (es) | Anticuerpos anti-ox40 y métodos de uso | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3221359T3 (da) | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof | |
| DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
| DK3500299T3 (da) | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3230319T3 (da) | Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3292153T3 (da) | Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling | |
| DK3468997T3 (da) | Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof |